XML 91 R52.htm IDEA: XBRL DOCUMENT v3.22.1
Fair Value of Financial Assets and Liabilities - Schedule of Fair Value of Warrants Issued (Details)
12 Months Ended
Jul. 16, 2021
$ / shares
Dec. 31, 2020
$ / shares
Dec. 31, 2021
$ / shares
Dragasac Warrant      
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]      
Exercise price $ 6.77 [1] $ 6.77 [1] $ 6.77
Term 3 years 8 months 1 day    
Series B Preferred Stock      
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]      
Exercise price $ 7.53 [2] 7.53 [2] 7.53
Term 3 years 8 months 1 day    
Minimum | Dragasac Warrant      
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]      
Fair value of common stock $ 9.66 $ 4.17  
Term   3 months 29 days  
Minimum | Series B Preferred Stock      
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]      
Fair value of common stock 9.66 $ 4.17  
Term   3 months 29 days  
Maximum | Dragasac Warrant      
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]      
Fair value of common stock 10.20 $ 6.95  
Term   1 year 3 months 29 days  
Maximum | Series B Preferred Stock      
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]      
Fair value of common stock 10.20 $ 6.95  
Term   1 year 3 months 29 days  
Sponsors Warrants      
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]      
Purchase price 10.20   5.12
Exercise price $ 11.50   $ 11.50
Term 5 years   4 years 6 months
Dividend Yield | Sponsors Warrants      
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]      
Warrants input 0   0
Risk-Free Interest Rate | Dragasac Warrant      
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]      
Warrants input 0.60    
Risk-Free Interest Rate | Series B Preferred Stock      
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]      
Warrants input 0.60    
Risk-Free Interest Rate | Minimum | Dragasac Warrant      
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]      
Warrants input   0.09  
Risk-Free Interest Rate | Minimum | Series B Preferred Stock      
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]      
Warrants input   0.09  
Risk-Free Interest Rate | Maximum | Dragasac Warrant      
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]      
Warrants input   0.10  
Risk-Free Interest Rate | Maximum | Series B Preferred Stock      
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]      
Warrants input   0.10  
Risk-Free Interest Rate | Sponsors Warrants      
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]      
Warrants input 0.79   1.19
Volatility | Dragasac Warrant      
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]      
Warrants input 54 90  
Volatility | Series B Preferred Stock      
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]      
Warrants input 54 90  
Volatility | Sponsors Warrants      
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]      
Warrants input 50.0   63.0
[1] The exercise price is the lower of $6.77 per share or 80% of either (i) the value attributed to one share of Legacy Celularity Series B Preferred Stock upon a consummation of a change of control or the closing of a strategic transaction or (ii) the price at which one share of Legacy Celularity common stock is sold to the public in an initial public offering. As amended on March 16, 2020, the warrants are exercisable on the first to occur of (a) March 16, 2025, (b) the consummation of Legacy Celularity’s initial public offering, (c) the consummation of a change of control and (d) the closing of a strategic transaction pursuant to which Legacy Celularity’s stockholders exchange their existing shares of capital stock in Legacy Celularity for shares in a company whose shares are listed on a national stock exchange.
[2] The warrants are exercisable at a price of $7.53 per share on the first to occur of: (a) the 60-month anniversary of the date of issuance of the warrants, (b) the consummation of an agreement for a public exit event, and (c) the consummation of a change of control.